Revolution Medicines to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Revolution Medicines (Nasdaq: RVMD), a clinical-stage oncology company focused on RAS-addicted cancers, announces its participation in two major healthcare conferences. CEO Mark A. Goldsmith will present at Guggenheim's Inaugural Healthcare Innovation Conference on November 12, 2024, at 3:00 p.m. ET in Boston, and the UBS Global Healthcare Conference on November 13, 2024, at 5:00 p.m. ET in Rancho Palos Verdes. Both presentations will be available via webcast on the company's website, with replays accessible for at least 14 days after the events.

News Market Reaction

+1.58%

1 alert

+1.58% News Effect

On the day this news was published, RVMD gained 1.58%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

REDWOOD CITY, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will be a featured speaker at Guggenheim's Inaugural Healthcare Innovation Conference and the UBS Global Healthcare Conference.

Details of the company’s participation are as follows:

• Guggenheim's Inaugural Healthcare Innovation Conference
  

Conference Dates: November 11-13, 2024
Fireside Chat Time/Date: 3:00 p.m. ET on Tuesday, November 12, 2024
Location: Boston, MA; webcast available

• UBS Global Healthcare Conference
  

Conference Dates: November 11-14, 2024
Fireside Chat Time/Date: 5:00 p.m. ET on Wednesday, November 13, 2024
Location: Rancho Palos Verdes, CA; webcast available

To access the live webcasts, please visit the “Events & Presentations” page of Revolution Medicines’ website at https://ir.revmed.com/events-and-presentations. Additionally, a replay of the webcasts will be available on the “Events & Presentations” page of the Revolution Medicines website for at least 14 days following the conference.

About Revolution Medicines, Inc.
Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors RMC-6236, a RAS(ON) multi-selective inhibitor, RMC-6291, a RAS(ON) G12C-selective inhibitor, and RMC-9805, a RAS(ON) G12D-selective inhibitor, are currently in clinical development. Additional development opportunities in the company’s pipeline focus on RAS(ON) mutant-selective inhibitors, including RMC-5127 (G12V), RMC-0708 (Q61H) and RMC-8839 (G13C), in addition to RAS companion inhibitors RMC-4630 and RMC-5552.

FAQ

When is Revolution Medicines (RVMD) presenting at the Guggenheim Healthcare Conference in 2024?

Revolution Medicines will present at Guggenheim's Inaugural Healthcare Innovation Conference on Tuesday, November 12, 2024, at 3:00 p.m. ET in Boston, MA.

Where can I watch Revolution Medicines' (RVMD) healthcare conference webcasts in November 2024?

The webcasts can be accessed through the 'Events & Presentations' page on Revolution Medicines' website at ir.revmed.com/events-and-presentations, with replays available for 14 days after the conferences.

What healthcare conferences is Revolution Medicines (RVMD) attending in November 2024?

Revolution Medicines is participating in two conferences: Guggenheim's Inaugural Healthcare Innovation Conference (November 11-13) and the UBS Global Healthcare Conference (November 11-14).